


Appl. No. 10/030,735
 Amdt. dated November 11, 2005
 Amendment and Reply under 37 CFR 1.116 Expedited
 Procedure Examining Group 1644

PATENT

Amendments to the Specification:

Please replace the paragraph on page 16, beginning on line 22, with the following amended paragraph:

The present invention generally provides peptides, comprising the sequence



wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; the ~~X₁-X₂-X₃-X₄ sequence is selected from the group consisting of~~

~~N-V-R-V, N-V-R-I, N-V-R-L, N-V-R-F (SEQ ID NOS: 55-57 & 51),
 N-V-K-V, N-V-K-I, N-V-K-L, N-V-K-F (SEQ ID NOS: 58-61),
 N-I-R-V, N-I-R-I, N-I-R-L, N-I-R-F (SEQ ID NOS: 62-65),
 N-I-K-V, N-I-K-I, N-I-K-L, N-I-K-F (SEQ ID NOS: 66-69),
 N-L-R-V, N-L-R-I, N-L-R-L, N-L-R-F (SEQ ID NOS: 70-73),
 N-L-K-V, N-L-K-I, N-L-K-L, N-L-K-F (SEQ ID NOS: 74-77),
 Q-V-R-V, Q-V-R-I, Q-V-R-L, Q-V-R-F (SEQ ID NOS: 78-80 & 53),
 Q-V-K-V, Q-V-K-I, Q-V-K-L, Q-V-K-F (SEQ ID NOS: 81-83),
 Q-I-R-V, Q-I-R-I, Q-I-R-L, Q-I-R-F (SEQ ID NOS: 84-87),
 Q-I-K-V, Q-I-K-I, Q-I-K-L, Q-I-K-F (SEQ ID NOS: 88-91),
 Q-L-R-V, Q-L-R-I, Q-L-R-L, Q-L-R-F (SEQ ID NOS: 92-95),
 Q-L-K-V, Q-L-K-I, Q-L-K-L, Q-L-K-F (SEQ ID NOS: 96-99),
 D-V-R-V, D-V-R-I, D-V-R-L, D-V-R-F (SEQ ID NOS: 100-102 & 54),
 D-V-K-V, D-V-K-I, D-V-K-L, D-V-K-F (SEQ ID NOS: 103-106),~~

Appl. No. 10/030,735

PATENT

Amdt. dated November 11, 2005

Amendment and Reply under 37 CFR 1.116 Expedited

Procedure Examining Group 1644

~~D I R V, D I R I, D I R L, D I R F (SEQ ID NOS: 107-110),~~
~~D I K V, D I K I, D I K L, D I K F (SEQ ID NOS: 111-114),~~
~~D L R V, D L R I, D L R L, D L R F (SEQ ID NOS: 115-118),~~
~~D L K V, D L K I, D L K L, D L K F (SEQ ID NOS: 119-122),~~
~~S V R V, S V R I, S V R L, S V R F (SEQ ID NOS: 123-125 & 52),~~
~~S V K V, S V K I, S V K L, S V K F (SEQ ID NOS: 126-129),~~
~~S I R V, S I R I, S I R L, S I R F (SEQ ID NOS: 130-133),~~
~~S I K V, S I K I, S I K L, S I K F (SEQ ID NOS: 134-137),~~
~~S L R V, S L R I, S L R L, S L R F (SEQ ID NOS: 138-141),~~
~~S L K V, S L K I, S L K L, S L K F (SEQ ID NOS: 142-145),~~

R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. In one embodiment of the invention, peptides having the sequence FQGV LQNVR FVF (SEQ ID NO:6) or FRGCVRNLRLSR (SEQ ID NO:12) are specifically excluded. In one embodiment, the peptides contain from 4 to 12 amino acids, i.e., has a length of 4 to 12 amino acid residues. In one embodiment, the peptides comprise additional residues, e.g., typically up to a length of 15, 20, 25, or 40 residues that includes the core sequence (I).